Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors

By sjmartinez • March 9, 2023

McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong J, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors. Clin Cancer Res. 2023 Mar 8:CCR-22-2981. doi: 10.1158/1078-0432.CCR-22-2981. Epub ahead of print. PMID: 36884217.

Tags: Hematology/Oncology, Publications

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo[...]

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer

Lloyd MR, Chica-Parrado R, Weipert CM, Knepper TC, Podany EL, Napolitano F, Ye D, Lin CC, Uemoto Y, Liao J, Wegrzyn C, Walko CM, Ryan[...]

Finetuning Type I Interferon Signaling to Enhance T Cell Immunity in HIV Infection

Mu W, Kedia N, Zhen A. Finetuning Type I Interferon Signaling to Enhance T Cell Immunity in HIV Infection. Viruses. 2025 May 29;17(6):774. doi: 10.3390/v17060774.[...]